{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:45:41Z","timestamp":1790703941298,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"DOI":"10.7759\/cureus.98275","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:31:16Z","timestamp":1764649876000},"source":"Crossref","is-referenced-by-count":3,"title":["Antipsychotic Misuse: A Silent but Growing Public Health Hazard"],"prefix":"10.7759","author":[{"given":"Sumeet","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisma","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"McLenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10r06264yel","article-title":"Past and present progress in the pharmacologic treatment of schizophrenia","volume":"71","author":"Kane JM","year":"2010","unstructured":"Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010, 71:1115-24. 10.4088\/JCP.10r06264yel","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008","volume":"20","author":"Alexander GC","year":"2011","unstructured":"Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011, 20:177-84. 10.1002\/pds.2082","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis","volume":"306","author":"Maher AR","year":"2011","unstructured":"Maher AR, Maglione M, Bagley S, et al.. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA. 2011, 306:1359-69. 10.1001\/jama.2011.1360","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000381","article-title":"Factors associated with off-label utilization of second-generation antipsychotics among publicly insured adults","volume":"72","author":"Horvitz-Lennon M","year":"2021","unstructured":"Horvitz-Lennon M, Volya R, Hollands S, Zelevinsky K, Mulcahy A, Donohue JM, Normand ST. Factors associated with off-label utilization of second-generation antipsychotics among publicly insured adults. Psychiatr Serv. 2021, 72:1031-9. 10.1176\/appi.ps.202000381","journal-title":"Psychiatr Serv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert M","year":"2012","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012, 8:114-26. 10.1038\/nrendo.2011.156","journal-title":"Nat Rev Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2014.07.007","article-title":"Racial\/Ethnic disparities in monitoring metabolic parameters for patients with schizophrenia receiving antipsychotic medications","volume":"23","author":"Phillips KL","year":"2015","unstructured":"Phillips KL, Copeland LA, Zeber JE, Stock EM, Tsan JY, MacCarthy AA. Racial\/Ethnic disparities in monitoring metabolic parameters for patients with schizophrenia receiving antipsychotic medications. Am J Geriatr Psychiatry. 2015, 23:596-606. 10.1016\/j.jagp.2014.07.007","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2006.57.12.1693","article-title":"Antipsychotic use and expenditure in the United States","volume":"57","author":"Aparasu RR","year":"2006","unstructured":"Aparasu RR, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv. 2006, 57:1693. 10.1176\/ps.2006.57.12.1693","journal-title":"Psychiatr Serv"},{"key":"ref8","article-title":"Medicaid prescription drug spending in the 1990s: A decade of change","volume":"25","author":"Baugh DK","year":"2004","unstructured":"Baugh DK, Pine PL, Blackwell S, Ciborowski G. Medicaid prescription drug spending in the 1990s: A decade of change. Health Care Financ Rev. 2004, 25:5-23.","journal-title":"Health Care Financ Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson M","year":"2012","unstructured":"Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012, 69:1247-56. 10.1001\/archgenpsychiatry.2012.647","journal-title":"Arch Gen Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-197","article-title":"Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: Does the effect differ by dose?","volume":"11","author":"Ulcickas Yood M","year":"2011","unstructured":"Ulcickas Yood M, Delorenze GN, Quesenberry CP Jr, et al.. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: Does the effect differ by dose?. BMC Psychiatry. 2011, 11:197. 10.1186\/1471-244X-11-197","journal-title":"BMC Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon V","year":"2009","unstructured":"Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009, 70:1041-50. 10.4088\/jcp.08r04392","journal-title":"J Clin Psychiatry"},{"key":"ref12","article-title":"","author":"Stahl SM","year":"2021","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications. 5th ed. Cambridge University Press. 2021. http:\/\/chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.psychiatry.ru\/siteconst\/userfiles\/file\/book\/%D...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4525","article-title":"Metabolic profile and long-term risk of depression, anxiety, and stress-related disorders","volume":"7","author":"Chourpiliadis C","year":"2024","unstructured":"Chourpiliadis C, Zeng Y, Lovik A, et al.. Metabolic profile and long-term risk of depression, anxiety, and stress-related disorders. JAMA Netw Open. 2024, 7:e244525. 10.1001\/jamanetworkopen.2024.4525","journal-title":"JAMA Netw Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2017.26","article-title":"Cardiometabolic dysregulation and cognitive decline: Potential role of depressive symptoms","volume":"212","author":"Schmitz N","year":"2018","unstructured":"Schmitz N, Desch\u00eanes SS, Burns RJ, et al.. Cardiometabolic dysregulation and cognitive decline: Potential role of depressive symptoms. Br J Psychiatry. 2018, 212:96-102. 10.1192\/bjp.2017.26","journal-title":"Br J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.034","article-title":"Improving medication adherence in cardiometabolic disease: Practical and regulatory implications","volume":"69","author":"Ferdinand KC","year":"2017","unstructured":"Ferdinand KC, Senatore FF, Clayton-Jeter H, et al.. Improving medication adherence in cardiometabolic disease: Practical and regulatory implications. J Am Coll Cardiol. 2017, 69:437-51. 10.1016\/j.jacc.2016.11.034","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1593145","article-title":"Weight stigma and mental health in a racially and ethnically diverse sample of US adults","volume":"16","author":"Gerend MA","year":"2025","unstructured":"Gerend MA, Lu AW, Teets EL. Weight stigma and mental health in a racially and ethnically diverse sample of US adults. Front Psychiatry. 2025, 16:1593145. 10.3389\/fpsyt.2025.1593145","journal-title":"Front Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2018.01.18.1","article-title":"Long-term evolution of metabolic status in patients with schizophrenia stably maintained on second-generation antipsychotics","volume":"15","author":"Jeong SH","year":"2018","unstructured":"Jeong SH, Lee NY, Kim SH, et al.. Long-term evolution of metabolic status in patients with schizophrenia stably maintained on second-generation antipsychotics. Psychiatry Investig. 2018, 15:628-37. 10.30773\/pi.2018.01.18.1","journal-title":"Psychiatry Investig"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae054","article-title":"Severe mental illness: Cardiovascular risk assessment and management","volume":"45","author":"Polcwiartek C","year":"2024","unstructured":"Polcwiartek C, O'Gallagher K, Friedman DJ, Correll CU, Solmi M, Jensen SE, Nielsen RE. Severe mental illness: Cardiovascular risk assessment and management. Eur Heart J. 2024, 45:987-97. 10.1093\/eurheartj\/ehae054","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.00269.x","article-title":"Prevalence of depression in survivors of acute myocardial infarction","volume":"21","author":"Thombs BD","year":"2006","unstructured":"Thombs BD, Bass EB, Ford DE, et al.. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006, 21:30-8. 10.1111\/j.1525-1497.2005.00269.x","journal-title":"J Gen Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.670844","article-title":"Prevalence of poststroke cognitive impairment: South London Stroke Register 1995-2010","volume":"44","author":"Douiri A","year":"2013","unstructured":"Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995-2010. Stroke. 2013, 44:138-45. 10.1161\/STROKEAHA.112.670844","journal-title":"Stroke"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000162","article-title":"Depression and anxiety in heart failure: A review","volume":"26","author":"Celano CM","year":"2018","unstructured":"Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: A review. Harv Rev Psychiatry. 2018, 26:175-84. 10.1097\/HRP.0000000000000162","journal-title":"Harv Rev Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2101","article-title":"Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence","volume":"160","author":"DiMatteo MR","year":"2000","unstructured":"DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000, 160:2101-7. 10.1001\/archinte.160.14.2101","journal-title":"Arch Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.84524","article-title":"Understanding the links between cardiovascular and psychiatric conditions","volume":"11","author":"Amarasekera S","year":"2022","unstructured":"Amarasekera S, Jha P. Understanding the links between cardiovascular and psychiatric conditions. Elife. 2022, 11:10.7554\/eLife.84524","journal-title":"Elife"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis","volume":"72","author":"Walker ER","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry. 2015, 72:334-41. 10.1001\/jamapsychiatry.2014.2502","journal-title":"JAMA Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.623681","article-title":"The burden of antipsychotic-induced weight gain and metabolic syndrome in children","volume":"12","author":"Libowitz MR","year":"2021","unstructured":"Libowitz MR, Nurmi EL. The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry. 2021, 12:623681. 10.3389\/fpsyt.2021.623681","journal-title":"Front Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl SE","year":"2023","unstructured":"Hampl SE, Hassink SG, Skinner AC, et al.. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023, 151:e2022060640. 10.1542\/peds.2022-060640","journal-title":"Pediatrics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","year":"2011","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011, 128:S213-56. 10.1542\/peds.2009-2107C","journal-title":"Pediatrics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000536","article-title":"Childhood and adolescent adversity and cardiometabolic outcomes: a scientific statement from the American Heart Association","volume":"137","author":"Suglia SF","year":"2018","unstructured":"Suglia SF, Koenen KC, Boynton-Jarrett R, et al.. Childhood and adolescent adversity and cardiometabolic outcomes: a scientific statement from the American Heart Association. Circulation. 2018, 137:e15-28. 10.1161\/CIR.0000000000000536","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-019-0990-7","article-title":"Obesity in adolescents with psychiatric disorders","volume":"21","author":"Chao AM","year":"2019","unstructured":"Chao AM, Wadden TA, Berkowitz RI. Obesity in adolescents with psychiatric disorders. Curr Psychiatry Rep. 2019, 21:3. 10.1007\/s11920-019-0990-7","journal-title":"Curr Psychiatry Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng C","year":"2013","unstructured":"Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am. 2013, 42:545-63. 10.1016\/j.ecl.2013.05.006","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2014.07.004","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","author":"Ballon JS","year":"2014","unstructured":"Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014, 25:593-600. 10.1016\/j.tem.2014.07.004","journal-title":"Trends Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713002778","article-title":"Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables","volume":"44","author":"Vancampfort D","year":"2014","unstructured":"Vancampfort D, Correll CU, Wampers M, et al.. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables. Psychol Med. 2014, 44:2017-28. 10.1017\/S0033291713002778","journal-title":"Psychol Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll CU","year":"2017","unstructured":"Correll CU, Solmi M, Veronese N, et al.. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017, 16:163-80. 10.1002\/wps.20420","journal-title":"World Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-na\u00efve population","volume":"99","author":"Perez-Iglesias R","year":"2008","unstructured":"Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al.. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-na\u00efve population. Schizophr Res. 2008, 99:13-22. 10.1016\/j.schres.2007.10.022","journal-title":"Schizophr Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4205-9","article-title":"Diabetes screening among antipsychotic-treated adults with severe mental illness in an integrated delivery system: A retrospective cohort study","volume":"33","author":"Mangurian C","year":"2018","unstructured":"Mangurian C, Schillinger D, Newcomer JW, et al.. Diabetes screening among antipsychotic-treated adults with severe mental illness in an integrated delivery system: A retrospective cohort study. J Gen Intern Med. 2018, 33:79-86. 10.1007\/s11606-017-4205-9","journal-title":"J Gen Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.20120p202","article-title":"Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: An underestimated factor","volume":"63","author":"Jerrell JM","year":"2012","unstructured":"Jerrell JM, McIntyre RS, Black GB. Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: An underestimated factor. Psychiatr Serv. 2012, 63:202-4. 10.1176\/appi.ps.20120p202","journal-title":"Psychiatr Serv"},{"key":"ref37","article-title":"","author":"Stahl SM","year":"2021","unstructured":"Stahl SM. Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 6th ed. Cambridge University Press, 2021. https:\/\/books.google.co.in\/books?hl=en&lr=&id=HkA0Q31YDhAC&oi=fnd&pg=PR7&dq=Stahl%E2%80%99s+Essential+Psychopharmacol...."},{"key":"ref38","article-title":"eds. Biology in Psychiatry","author":"Trimble MR","year":"2010","unstructured":"Trimble MR, George MS. eds. Biology in Psychiatry. Cambridge University Press, 2010."},{"key":"ref39","article-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. 14th Edition","author":"Brunton LL","year":"2023","unstructured":"Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw-Hill Education, 2023."},{"key":"ref40","article-title":"","author":"Meyer JS","year":"2018","unstructured":"Meyer JS, Quenzer LF. Psychopharmacology: Drugs, the Brain and Behavior, 4th Edition . Sinauer Associates, 2018. https:\/\/cir.nii.ac.jp\/crid\/1970304959910055117."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2020.08.441","article-title":"Systematic review: System-wide interventions to monitor pediatric antipsychotic prescribing and promote best practice","volume":"60","author":"Mackie TI","year":"2021","unstructured":"Mackie TI, Schaefer AJ, Karpman HE, Lee SM, Bellonci C, Larson J. Systematic review: System-wide interventions to monitor pediatric antipsychotic prescribing and promote best practice. J Am Acad Child Adolesc Psychiatry. 2021, 60:76-104.e7. 10.1016\/j.jaac.2020.08.441","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201600489","article-title":"Second-generation antipsychotic prescribing patterns for pediatric patients enrolled in West Virginia Medicaid","volume":"68","author":"Melvin KE","year":"2017","unstructured":"Melvin KE, Hart JC, Sorvig RD. Second-generation antipsychotic prescribing patterns for pediatric patients enrolled in West Virginia Medicaid. Psychiatr Serv. 2017, 68:1061-7. 10.1176\/appi.ps.201600489","journal-title":"Psychiatr Serv"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13297","article-title":"Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children","volume":"55","author":"Akincigil A","year":"2020","unstructured":"Akincigil A, Mackie TI, Cook S, Hilt RJ, Crystal S. Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children. Health Serv Res. 2020, 55:596-603. 10.1111\/1475-6773.13297","journal-title":"Health Serv Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900089","article-title":"Quality measures for managing prescription of antipsychotic medication among youths: Factors associated with health plan performance","volume":"70","author":"Olin S","year":"2019","unstructured":"Olin S, Storfer-Isser A, Morden E, Yin Y, Altamirano L, Byron SC, Scholle SH. Quality measures for managing prescription of antipsychotic medication among youths: Factors associated with health plan performance. Psychiatr Serv. 2019, 70:1020-6. 10.1176\/appi.ps.201900089","journal-title":"Psychiatr Serv"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11029-5","article-title":"Incorporating clinician insight and care plans into an audit and feedback initiative for antipsychotic prescribing to Medicaid-enrolled youth in Philadelphia","volume":"24","author":"Candon M","year":"2024","unstructured":"Candon M, Shen S, Rothbard A, et al.. Incorporating clinician insight and care plans into an audit and feedback initiative for antipsychotic prescribing to Medicaid-enrolled youth in Philadelphia. BMC Health Serv Res. 2024, 24:574. 10.1186\/s12913-024-11029-5","journal-title":"BMC Health Serv Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03533-3","article-title":"Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018","volume":"21","author":"Candon M","year":"2021","unstructured":"Candon M, Shen S, Fadeyibi O, Smith JL, Rothbard A. Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018. BMC Psychiatry. 2021, 21:524. 10.1186\/s12888-021-03533-3","journal-title":"BMC Psychiatry"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.0379","article-title":"Association of the Centers for Medicare & Medicaid Services\u2019 National Partnership to Improve Dementia Care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014","volume":"178","author":"Maust DT","year":"2018","unstructured":"Maust DT, Kim HM, Chiang C, Kales HC. Association of the Centers for Medicare & Medicaid Services\u2019 National Partnership to Improve Dementia Care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Intern Med. 2018, 178:640-7. 10.1001\/jamainternmed.2018.0379","journal-title":"JAMA Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18276","article-title":"Unintended impacts of a national antipsychotic reduction initiative among nursing facility residents with and without Alzheimer's disease","volume":"71","author":"Wastila L","year":"2023","unstructured":"Wastila L, Qato DM, Fleming S, et al.. Unintended impacts of a national antipsychotic reduction initiative among nursing facility residents with and without Alzheimer's disease. J Am Geriatr Soc. 2023, 71:1714-23. 10.1111\/jgs.18276","journal-title":"J Am Geriatr Soc"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.1439","article-title":"CMS strategies to reduce antipsychotic drug use in nursing home patients with dementia show some progress","volume":"36","author":"Lucas JA","year":"2017","unstructured":"Lucas JA, Bowblis JR. CMS strategies to reduce antipsychotic drug use in nursing home patients with dementia show some progress. Health Aff (Millwood). 2017, 36:1299-308. 10.1377\/hlthaff.2016.1439","journal-title":"Health Aff (Millwood)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5032","article-title":"Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth","volume":"29","author":"Spence O","year":"2020","unstructured":"Spence O, Reeves G, dosReis S. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth. Pharmacoepidemiol Drug Saf. 2020, 29:1064-71. 10.1002\/pds.5032","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150619092903","article-title":"Off-label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends","volume":"21","author":"Carton L","year":"2015","unstructured":"Carton L, Cottencin O, Lapeyre-Mestre M, et al.. Off-label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends. Curr Pharm Des. 2015, 21:3280-97. 10.2174\/1381612821666150619092903","journal-title":"Curr Pharm Des"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198363","article-title":"Patterns and predictors of off-label prescription of psychiatric drugs","volume":"13","author":"Vijay A","year":"2018","unstructured":"Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018, 13:e0198363. 10.1371\/journal.pone.0198363","journal-title":"PLoS One"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.1867","article-title":"Effect of peer comparison letters for high-volume primary care prescribers of quetiapine in older and disabled adults: a randomized clinical trial","volume":"75","author":"Sacarny A","year":"2018","unstructured":"Sacarny A, Barnett ML, Le J, Tetkoski F, Yokum D, Agrawal S. Effect of peer comparison letters for high-volume primary care prescribers of quetiapine in older and disabled adults: a randomized clinical trial. JAMA Psychiatry. 2018, 75:1003-11. 10.1001\/jamapsychiatry.2018.1867","journal-title":"JAMA Psychiatry"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234149","article-title":"The effectiveness of behavioral economics-informed interventions on physician behavioral change: A systematic literature review","volume":"15","author":"Wang SY","year":"2020","unstructured":"Wang SY, Groene O. The effectiveness of behavioral economics-informed interventions on physician behavioral change: A systematic literature review. PLoS One. 2020, 15:e0234149. 10.1371\/journal.pone.0234149","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294974","article-title":"Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom","volume":"19","author":"Woodall AA","year":"2024","unstructured":"Woodall AA, Abuzour AS, Wilson SA, et al.. Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom. PLoS One. 2024, 19:e0294974. 10.1371\/journal.pone.0294974","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02990-6","article-title":"Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: A systematic review","volume":"20","author":"Ali RA","year":"2020","unstructured":"Ali RA, Jalal Z, Paudyal V. Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: A systematic review. BMC Psychiatry. 2020, 20:581. 10.1186\/s12888-020-02990-6","journal-title":"BMC Psychiatry"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-021-02658-z","article-title":"Perceived knowledge of psychiatry and family medicine residents regarding medical management of schizophrenia, hypertension, diabetes mellitus, and dyslipidemia: opportunities to refine the residency training","volume":"21","author":"Ying J","year":"2021","unstructured":"Ying J, Wan J, Sim K, Seah ED, Subramaniam M. Perceived knowledge of psychiatry and family medicine residents regarding medical management of schizophrenia, hypertension, diabetes mellitus, and dyslipidemia: opportunities to refine the residency training. BMC Med Educ. 2021, 21:232. 10.1186\/s12909-021-02658-z","journal-title":"BMC Med Educ"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2019.03.180176","article-title":"Opinions of primary care clinicians and psychiatrists on monitoring the metabolic effects of antipsychotics","volume":"32","author":"Mangurian C","year":"2019","unstructured":"Mangurian C, Giwa A, Brosey E, et al.. Opinions of primary care clinicians and psychiatrists on monitoring the metabolic effects of antipsychotics. J Am Board Fam Med. 2019, 32:418-23. 10.3122\/jabfm.2019.03.180176","journal-title":"J Am Board Fam Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3967-9","article-title":"Closing the false divide: Sustainable approaches to integrating mental health services into primary care","volume":"32","author":"Kroenke K","year":"2017","unstructured":"Kroenke K, Unutzer J. Closing the false divide: Sustainable approaches to integrating mental health services into primary care. J Gen Intern Med. 2017, 32:404-10. 10.1007\/s11606-016-3967-9","journal-title":"J Gen Intern Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2023.111383","article-title":"Comparison of medical treatment of patients with schizophrenia in general practitioners' clinics versus mental health clinics: A cohort study","volume":"171","author":"Gur S","year":"2023","unstructured":"Gur S, Weizman S, Hermesh H, Matalon A, Meyerovitch J, Krivoy A. Comparison of medical treatment of patients with schizophrenia in general practitioners' clinics versus mental health clinics: A cohort study. J Psychosom Res. 2023, 171:111383. 10.1016\/j.jpsychores.2023.111383","journal-title":"J Psychosom Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700255","article-title":"Management of common medical conditions by office-based psychiatrists","volume":"69","author":"Mojtabai R","year":"2018","unstructured":"Mojtabai R, Olfson M. Management of common medical conditions by office-based psychiatrists. Psychiatr Serv. 2018, 69:410-23. 10.1176\/appi.ps.201700255","journal-title":"Psychiatr Serv"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218711","article-title":"Mental health professionals' views and experiences of antipsychotic reduction and discontinuation","volume":"14","author":"Cooper RE","year":"2019","unstructured":"Cooper RE, Hanratty \u00c9, Morant N, Moncrieff J. Mental health professionals' views and experiences of antipsychotic reduction and discontinuation. PLoS One. 2019, 14:e0218711. 10.1371\/journal.pone.0218711","journal-title":"PLoS One"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116685","article-title":"Self-reported attitudes and strategies of physicians towards medication reduction and discontinuation","volume":"352","author":"Koch T","year":"2025","unstructured":"Koch T, von Peter S, Weinmann S, Ruiz-P\u00e9rez G. Self-reported attitudes and strategies of physicians towards medication reduction and discontinuation. Psychiatry Res. 2025, 352:116685. 10.1016\/j.psychres.2025.116685","journal-title":"Psychiatry Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003784","article-title":"National trends in off-label use of atypical antipsychotics in children and adolescents in the United States","volume":"95","author":"Sohn M","year":"2016","unstructured":"Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine. 2016, 95:e3784. 10.1097\/MD.0000000000003784","journal-title":"Medicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/428295-antipsychotic-misuse-a-silent-but-growing-public-health-hazard","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:31:20Z","timestamp":1764649880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/428295-antipsychotic-misuse-a-silent-but-growing-public-health-hazard"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":64,"URL":"https:\/\/doi.org\/10.7759\/cureus.98275","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}